Navigation Links
Pharmaleads' Lead Candidate for Pain, PL37, Enters Phase I
Date:10/2/2008

PARIS, October 2 /PRNewswire/ -- Pharmaleads has obtained from the French Medicine Agency (AFSSAPS) the authorization to perform a single ascending dose Phase I study with PL37, its lead compound for oral treatment of neuropathic pain.

Neuropathic pain is a major chronic pain condition, with an estimated prevalence in the world's population of up to 6%, according to the most recent surveys, with many causes such as shingles, herpes, diabetes, antiviral or antitumor chemotherapy surgery, or low back disorders. Neuropathic pain does not respond well to usual painkillers. Worldwide market for neuropathic pain is estimated to reach 5 billion USD by 2010.

This compound originates from the work of Pharmaleads' chief scientists, Professors Bernard P. Roques and Marie-Claude Fournie-Zaluski, and is a dual inhibitor of both enzymes responsible for the rapid degradation of enkephalins, the endogenous opiates. It therefore elicits an analgesic effect wherever enkephalins are produced as a response to a painful stimulus, and maintains a high level of these natural analgesic substances by preventing their rapid degradation.

According to Thierry Bourbie, Chairman and CEO of Pharmaleads, "PL37 is Pharmaleads' first compound to enter clinical development and the first representative of a totally new class of painkillers, hence confirming the validity of our science and chemistry, as well as our capabilities as a drug development company. Neuropathic pain remains poorly treated and there is an urgent need to develop and bring to patients and doctors a specific oral treatment that would be really active and well tolerated. This looks very promising."

Bernard P. Roques, Vice-President and CSO of Pharmaleads explains: "The inhibition of both enzymes, responsible for the inactivation, in the body, of naturally present opiates, enhances their analgesic properties. PL37 physiological action in all areas where pain is present leads to very promising properties in peripheral neuropathic disorders."

Michel Wurm, M.D., Director of Corporate Development at Pharmaleads stated: "Pre-clinical studies have demonstrated the safety and efficacy of PL37 across all known models for neuropathic pain. The bioavailability of this oral compound is remarkable, as is its safety margin. We hope to complete Phase I in less than a year, including early pharmacodynamic testing in healthy volunteers."

The pre-clinical program was financed with the support of OSEO, the French Public Research Financing Institution.

About Pharmaleads:

Pharmaleads is a pharmaceutical company focusing on research and early development of small molecules. Headquartered in Paris, France, Pharmaleads was founded in 2001 by Professors Bernard P. Roques, pharmacist and PhD in chemistry, Member of the French Academy of Sciences, and Marie-Claude Fournie-Zaluski, PhD in chemistry, both of them inventors of drugs (2 on the market). They were joined in 2004 by Thierry Bourbie, alumnus from Polytechnique and Mines, PhD from Stanford, (former Deputy General Manager, Suez Group) and Jean-Pierre Rogala, PhD from Agro, MBA from MIT (IBM, Suez Group). They were able to bring in their first rank international business expertise to fully unleash the world-class capabilities of the company in pharmacology and medicinal chemistry. In 2006, Michel Wurm, M.D. joined and added his extensive experience in drug and business development.

For further information, please contact:

PHARMALEADS YUCATAN

Michel Wurm, MD, Annie-Florence Loyer

Director, Corporate Development +33-1-53-63-27-29

+33-1-440-670-04 afloyer@yucatan.tm.fr

michel.wurm@pharmaleads.com

http://www.pharmaleads.com


'/>"/>
SOURCE Pharmaleads
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Potentia Pharmaceuticals Announces Positive Safety Data and Study Expansion in Phase I Trial for Lead Drug Candidate POT-4
2. Quark Pharmaceuticals Announces First RNAi Drug Candidate Having a Novel, Proprietary Structure Covered by Quark Intellectual Property
3. Data from In Vivo Disease Models on Taligen Therapeutics Pipeline Candidates to be Presented at the XXII International Complement Workshop
4. Enobia Pharma Receives FDA Orphan Drug Designation for Hypophosphatasia Product Candidate ENB-0040
5. InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
6. Bionovo Reports on Metabolic Studies Related to Its Menopausal Hot Flash Drug Candidate
7. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
8. BioVex Announces Regulatory Clearance to Commence a Clinical Study With ImmunoVEX HSV2; A Vaccine Candidate for Genital Herpes
9. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
10. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
11. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... 2017 Diplomat Pharmacy, Inc. (NYSE: ... Consulting, LLC , and named its founder as Diplomat,s ... Tennessee , will operate under Diplomat ... service offerings for health care partners to include IT ... "In an interoperable world, technology delivers comprehensive ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob ... sciatica in a new episode of "Success Files," which is an award-winning educational ... and investigates each subject in-depth with passion and integrity. , Sciatica occurs when ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare Compliance (FHC), an ... showcase a range of technology and learning solutions at the 68th Annual American ... to be held October 14–18, 2017 at the Mandalay Bay Resort in Las ...
(Date:10/12/2017)... ... , ... IsoComforter, Inc. ( https://isocomforter.com ), one of the Nation’s ... design of the shoulder pad. The shoulder pad provides optimal support and full ... while using cold therapy. By utilizing ice and water that is circulated from an ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... Mohebi Hair Restoration, has recently contributed a medical article to the newly revamped ... cosmetictown.com. Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular ...
(Date:10/12/2017)... ... October 12, 2017 , ... Women-owned and Grand Rapids-based workplace ... Brightest in Wellness® by Best and Brightest. OnSite Wellness will be honored at ... from 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located ...
Breaking Medicine News(10 mins):